Ritonavir

This classification denotes a protease inhibitor with the molecular formula C37H48N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3J8G9O825, chemically known as 2,4,7,12-tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5s-(5r*,8r*,10r*,11r*))- but generally known as ritonavir, which bears US NIH Compound Identifier 60954. European Medicines Agency schedules Ritonavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10342MIG. The term RITONAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules ritonavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ritonavir under HS 29341000 and SITC 51579. As of Q4 2014, RITONAVIR remains the US FDA Preferred Term for this commodity. Ritonavir bears US NLM identifiers UMLS ID C0292818 and NCI Concept Code C1609. SMILES: S1C(NC(CN(C(=O)NC(C(C)C)C(=O)NC(CC(O)C(NC(=O)OCC2SCNC2)CC2CCCCC2)CC2CCCCC2)C)C1)C(C)C.